UBS AM
FRTX

UBS AM’s Fresh Tracks Therapeutics, Inc. Common Stock FRTX Stock Holding History

UBS AM’s Portfolio FRTX Stock Details FRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5
Closed -$20K – 2567
2013
Q3 		$20K Hold
5
– – ﹤0.01% 2500
2013
Q2 		$51K Buy
+5
New +$55.4K ﹤0.01% 2440

Other funds holding FRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

UBS AM's FRTX Position: Q4 2013 in Review

UBS AM sold out of Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) in Q4 2013, closing a stake of 5 shares — an estimated $20K sold.

UBS AM first reported a position in FRTX in Q2 2013 and held it in 2 quarters. The position peaked at $51K in Q2 2013. 79 funds tracked by Wall St. Rank hold FRTX as of Q4 2013.

  • UBS AM reported no remaining Fresh Tracks Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • UBS AM sold 5 Fresh Tracks Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $20K.
  • UBS AM first reported a position in Fresh Tracks Therapeutics, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • UBS AM's Fresh Tracks Therapeutics, Inc. Common Stock position peaked at $51K in Q2 2013.
  • 79 funds tracked by Wall St. Rank held Fresh Tracks Therapeutics, Inc. Common Stock as of Q4 2013.

Based on UBS AM's 13F filing for Q4 2013, filed 31 Jan 2014.